Last reviewed · How we verify
SHR-1819
SHR-1819 is a small molecule drug that targets the molecular target.
SHR-1819 is a small molecule drug that targets the molecular target. Used for Unknown.
At a glance
| Generic name | SHR-1819 |
|---|---|
| Sponsor | Guangdong Hengrui Pharmaceutical Co., Ltd |
| Drug class | Small molecule |
| Target | Unknown |
| Modality | Small molecule |
| Therapeutic area | Unknown |
| Phase | Phase 3 |
Mechanism of action
SHR-1819 works by binding to the molecular target, which leads to a specific biological response. This response is thought to be beneficial for the treatment of certain conditions.
Approved indications
- Unknown
Common side effects
- Unknown
Key clinical trials
- A Study to Extend Efficacy and Safety of SHR-1819 Injection in Adult Patients With Moderate to Severe Atopic Dermatitis (PHASE2)
- A Study of SHR-1819 in Patients With Moderate-to-severe Atopic Dermatitis (PHASE2)
- A Phase III Study of SHR-1819 Injection in Adolescents With Severe Atopic Dermatitis (PHASE3)
- A Study on the Bioavailability of SHR-1819 Injection Administered Subcutaneously Using Different Injection Devices in Healthy Subjects (PHASE1)
- Efficacy and Safety Study of SHR-1819 Injection in Adult Patients With Severe Atopic Dermatitis (PHASE3)
- A Clinical Study on the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of SHR-1819 Injection in Patients With Seasonal Allergic Rhinitis (PHASE2)
- A Phase Ib/II Study to Investigate the Safety of SHR-1819 in Children and Adolescents With Moderate-to-severe Atopic Dermatitis (PHASE1, PHASE2)
- Clinical Study of the Efficacy and Safety of SHR-1819 Injection in Adult Patients With Prurigo Nodularis (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |